Yes. IMO the TAM model that will be used in partnering discussion is likely to show the retreatment revenue (existing patients) quickly becomes higher than initial treatment (new patient) revenue. For example, within 5 years of marketing approval and it then compounds each year thereafter.
Not even CSL had this upside.
Ann: Quarterly Update and Appendix 4C - quarterly, page-24
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.0¢ | $66.23K | 276.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 26088 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 30637 | 2 |
View Market Depth
| Last trade - 11.22am 18/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |